Your browser doesn't support javascript.
loading
Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.
Martini, Carmela; Logan, Jessica M; Sorvina, Alexandra; Gordon, Colin; Beck, Andrew R; S-Y Ung, Ben; Caruso, Maria C; Moore, Courtney; Hocking, Ashleigh; Johnson, Ian R D; Li, Ka Lok; Karageorgos, Litsa; Hopkins, Ashley M; Esterman, Adrian J; Huzzell, Chelsea; Brooks, Robert D; Lazniewska, Joanna; Hickey, Shane M; Bader, Christie; Parkinson-Lawrence, Emma; Weigert, Roberto; Sorich, Michael J; Tewari, Prerna; Martin, Cara; O'Toole, Sharon; Bates, Mark; Ward, Mark; Mohammed, Bashir; Keegan, Helen; Watson, William; Prendergast, Sophie; Heffernan, Sheena; NiMhaolcatha, Sarah; O'Connor, Roisin; Malone, Victoria; Carter, Marguerite; Ryan, Katie; Brady, Nathan; Clarke, Andres; Sokol, Filip; Prabhakaran, Sarita; Stahl, Jürgen; Klebe, Sonja; Samaratunga, Hemamali; Delahunt, Brett; Selemidis, Stavros; Moretti, Kim L; Butler, Lisa M; O'Leary, John J; Brooks, Douglas A.
Afiliación
  • Martini C; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia. Electronic address: carmela.martino@unisa.edu.au.
  • Logan JM; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Sorvina A; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Gordon C; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Beck AR; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • S-Y Ung B; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Caruso MC; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Moore C; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Hocking A; Department of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
  • Johnson IRD; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Li KL; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Karageorgos L; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Hopkins AM; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, Australia.
  • Esterman AJ; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Huzzell C; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Brooks RD; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Lazniewska J; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Hickey SM; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Bader C; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Parkinson-Lawrence E; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Weigert R; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Sorich MJ; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, Australia.
  • Tewari P; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Martin C; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • O'Toole S; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Bates M; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Ward M; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Mohammed B; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Keegan H; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Watson W; University College Dublin, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland.
  • Prendergast S; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Heffernan S; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • NiMhaolcatha S; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • O'Connor R; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Malone V; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Carter M; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Ryan K; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Brady N; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Clarke A; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Sokol F; Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
  • Prabhakaran S; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia; Department of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
  • Stahl J; Department of Cytopathology and Histopathology, Clinpath Pathology, Adelaide, SA, Australia.
  • Klebe S; Department of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia; Department of Surgical Pathology, SA Pathology at Flinders Medical Centre, Adelaide, SA, Australia.
  • Samaratunga H; Aquesta Uropathology and the University of Queensland, Brisbane, Qld, Australia.
  • Delahunt B; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
  • Selemidis S; School of Health and Biomedical Sciences, STEM College, RMIT University, Bundoora, Melbourne, Vic, Australia.
  • Moretti KL; Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia; University of South Australia, Adelaide, SA, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia.
  • Butler LM; South Australian ImmunoGENomics Cancer Institute and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA, Australia; Solid Tumour Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
  • O'Leary JJ; Department of Histopathology, Trinity College Dublin, Dublin, Ireland.
  • Brooks DA; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Pathology ; 55(1): 40-51, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36089417
Diagnosis and assessment of patients with prostate cancer is dependent on accurate interpretation and grading of histopathology. However, morphology does not necessarily reflect the complex biological changes occurring in prostate cancer disease progression, and current biomarkers have demonstrated limited clinical utility in patient assessment. This study aimed to develop biomarkers that accurately define prostate cancer biology by distinguishing specific pathological features that enable reliable interpretation of pathology for accurate Gleason grading of patients. Online gene expression databases were interrogated and a pathogenic pathway for prostate cancer was identified. The protein expression of key genes in the pathway, including adaptor protein containing a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper motif 1 (Appl1), Sortilin and Syndecan-1, was examined by immunohistochemistry (IHC) in a pilot study of 29 patients with prostate cancer, using monoclonal antibodies designed against unique epitopes. Appl1, Sortilin, and Syndecan-1 expression was first assessed in a tissue microarray cohort of 112 patient samples, demonstrating that the monoclonal antibodies clearly illustrate gland morphologies. To determine the impact of a novel IHC-assisted interpretation (the utility of Appl1, Sortilin, and Syndecan-1 labelling as a panel) of Gleason grading, versus standard haematoxylin and eosin (H&E) Gleason grade assignment, a radical prostatectomy sample cohort comprising 114 patients was assessed. In comparison to H&E, the utility of the biomarker panel reduced subjectivity in interpretation of prostate cancer tissue morphology and improved the reliability of pathology assessment, resulting in Gleason grade redistribution for 41% of patient samples. Importantly, for equivocal IHC-assisted labelling and H&E staining results, the cancer morphology interpretation could be more accurately applied upon re-review of the H&E tissue sections. This study addresses a key issue in the field of prostate cancer pathology by presenting a novel combination of three biomarkers and has the potential to transform clinical pathology practice by standardising the interpretation of the tissue morphology.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Sindecano-1 Límite: Humans / Male Idioma: En Revista: Pathology Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Sindecano-1 Límite: Humans / Male Idioma: En Revista: Pathology Año: 2023 Tipo del documento: Article